Announcements Trials
Browse Landscape

Phase

Phase 3 15Phase NA 11Phase 1 11Phase 2/3 7Phase 2 5Phase 1/2 5Phase EARLY_PHASE1 4Phase 4 3

Status

Completed 16Terminated 6Recruiting 5Active not recruiting 3Not yet recruiting 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 282Prostatic Neoplasms 160Colorectal Neoplasms 155Carcinoma, Hepatocellular 144Neoplasms 134Leukemia, Myeloid, Acute 132Lung Neoplasms 115Squamous Cell Carcinoma of Head and Neck 108Triple Negative Breast Neoplasms 102Multiple Myeloma 102Recurrence 99Pancreatic Neoplasms 94Stomach Neoplasms 93Ovarian Neoplasms 87Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 68Esophageal Neoplasms 67Uterine Cervical Neoplasms 66Melanoma 65Brain Neoplasms 65Rectal Neoplasms 62Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 57Lymphoma 55Myelodysplastic Syndromes 54Esophageal Squamous Cell Carcinoma 54

Interventions

inebilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Myasthenia Gravis × Clear all
NCT07284420 2026-06-03

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

argenx

Phase 2 Recruiting
70 enrolled

Myasthenia Gravis

NCT06987539 2026-05-29

THYME

Amgen

Phase 2 Recruiting
15 enrolled

Myasthenia Gravis

NCT07501702 2026-05-18

ETNA

Vertex Pharmaceuticals Incorporated

Phase 2 Recruiting
30 enrolled

Myasthenia Gravis

NCT06414954 2026-04-13

SYNAPSE-MG

NMD Pharma A/S

Phase 2 Recruiting
84 enrolled

Myasthenia Gravis

NCT05067348 2025-05-01

tMG

Tang-Du Hospital

Phase 2 Recruiting
64 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡